Showing 5441-5450 of 5621 results for "".
- Silgan Dispensing Introduces Iridya Eye Dropper to Ensure Accurate Doses Down to the Drophttps://modernod.com/news/silgan-dispensing-introduces-iridya-eye-dropper-to-ensure-accurate-doses-down-to-the-drop/2479804/Silgan Dispensing has launched Iridya, a next-generation, multi-dose preservative-free eye dropper. The Iridya eye dropper ensures consumers an accurate dose and an easy-to-use design, while also providing safe delivery of ophthalmic medication. Its elongated tip provides greater accuracy when di
- Johnson & Johnson Vision Launches Worldwide Campaign to #SpotlightSight in Honor of World Sight Dayhttps://modernod.com/news/johnson-johnson-vision-launches-worldwide-campaign-to-spotlightsight-in-honor-of-world-sight-day/2479805/Sight is the most prized of all human senses. Yet, there are many people who do not fully experience the wonder of this gift. Nearly 285 million people around the world face impaired vision, and 80 percent of those cases are preventable with early diagnosis and treatment. That’s why Johnson
- High Dose of Sildenafil Tied to Long-term Retinal Damage in Case Reporthttps://modernod.com/news/high-dose-of-sildenafil-tied-to-long-term-retinal-damage-in-case-report/2479814/A patient who took a high dose of the erectile dysfunction drug sildenafil citrate developed long-term, and possibly irreversible, retinal damage with bilateral multicolored photopsia (perceived flashes of light) and erythropsia (red-tinted vision), according to a
- Regenxbio Completes Dosing of Fourth Cohort in Phase 1 Trial of RGX-314 Gene Therapy for Wet AMDhttps://modernod.com/news/regenxbio-completes-dosing-of-fourth-cohort-in-phase-1-trial-of-rgx-314-gene-therapy-for-wet-amd/2479815/Regenxbio announced it has completed dosing of the fourth cohort of six patients in a phase 1 clinical trial evaluating RGX-314 for the treatment of wet age-related macular degeneration (AMD). A total of 24 subjects have been dosed in the trial. The company also announced that an updated summary
- Ophthotech Completes Patient Recruitment for Its Phase 2b Clinical Trial of Zimura for Geographic Atrophy Secondary to Dry AMDhttps://modernod.com/news/ophthotech-completes-patient-recruitment-for-its-phase-2b-clinical-trial-of-zimura-for-geographic-atrophy-secondary-to-dry-amd/2479816/Ophthotech announced completion of patient recruitment for its phase 2b clinical trial of Zimura (avacincaptad pegol), the company’s complement factor C5 inhibitor, monotherapy in patients with geographic atrophy secondary to dry age-related macular degeneration (AMD). Complement factor C5
- Alcon Introduces Enhanced WaveLight Refractive Suitehttps://modernod.com/news/alcon-introduces-enhanced-wavelight-refractive-suite/2479821/Alcon unveiled software and hardware enhancements to the WaveLight Refractive Suite designed to provide surgeons and patients a more comfortable and efficient LASIK experience. The new platform offers a modernized user interface, ergonomic design, and expanded equipment color options. “Al
- Eyenuk Expands into Germany with Launch of EyeArt Artificial Intelligence Eye Screening for Diabetic Retinopathyhttps://modernod.com/news/eyenuk-expands-into-germany-with-launch-of-eyeart-artificial-intelligence-eye-screening-for-diabetic-retinopathy/2479826/Eyenuk announced its expansion into Germany with the adoption of EyeArt artificial intelligence (AI) technology for the screening of diabetic retinopathy at Diabetes Center Mergentheim in Bad Mergentheim, Germany. The center is the first dedicated diabetic clinic in Germany to use artificial inte
- The Vision Council Conducts Study on Contact Lens Subscription Serviceshttps://modernod.com/news/the-vision-council-conducts-study-on-contact-lens-subscription-services/2479830/The Vision Council’s market research team has developed an industry first look at the new and emerging contact lens subscription services. This study aims to examine the potential impact on the contact lens and optical retail industries. “We have recently seen several new contact lens subs
- CooperVision Introduces Online Training to Help ECPs Upgrade Contact Lens Patients to Silicone Hydrogel 1-Day Lenseshttps://modernod.com/news/coopervision-introduces-online-training-to-help-ecps-upgrade-contact-lens-patients-to-silicone-hydrogel-1-day-lenses/2479834/To help eye care professionals grow their silicone hydrogel 1-day contact lens business, CooperVision is unveiling a new, comprehensive online training program that can be completed at any place and time. The web-based training and on-demand webinar focus on teaching practitioners and staff how t
- First FDA-Approved Iris Prosthesis Now Available in the United Stateshttps://modernod.com/news/veo-ophthalmics-launches-customflex-artificialiris-in-the-united-states/2479835/VEO Ophthalmics announced the launch of the ‘Customflex ArtificialIris,’ the first iris prosthesis available in the United States. The surgically implanted device received FDA approval on May 30, 2018 for use in children and adults for the treatment of iris defects resulting from cong